David S Liu. PhD, FRACS
@DrDavidSLiu
Followers
599
Following
629
Media
50
Statuses
513
Oesophago-Gastric, Bariatric and General Surgeon | Researcher | Loving dad and husband
Heidelberg, Parkville, Melb
Joined January 2021
We are "crowd-sourcing" an International Fellowships Database for esophageal surgery, medicine and research. If your team offers fellowship opportunities, we invite you to join a global platform that brings together institutions from around the world! ➡️ https://t.co/KhnnpZ9Bhz
2
14
27
Final OS analysis of KN585 published in @JCO_ASCO @ASCO. OS HR has been changed from 0.90 at primary @TheLancetOncol to 0.86. HR in FLOT cohort also shifted from 1.02 to 0.81. Hoping MATTERHORN OS HR will also further improve with longer follow-up. https://t.co/cFqg6zkl1n
3
24
113
Lorenzo Ferri, ISDS President: Our strength as a society comes from sharing our expertise and learning from one another. I encourage every one of you to submit your work, be part of the conversation, and help shape the future of our specialty. 🔗 https://t.co/vt0BVfO6HJ
0
4
8
Only 4 days to the end of EARLY BIRD Registrations for this year's jam packed AANZGOSA Conference, Brisbane, 17th Sept. Just before @ISDE_net 2 birds, 1 stone: Come to both! Get online now and register: https://t.co/x6CIiK5UxB
https://t.co/xjlkGnXdS0
1
2
6
Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer... https://t.co/lNe0glc9aD Led by very talented @josephjzhao and Kennedy Ng. @sundar__raghav
0
10
35
Effects of postoperative complications in oesophageal cancer on survival, hospital outcomes, and long-term quality of life: retrospective cohort study ➡️ https://t.co/XTEoDQ21so This study evaluated the impact of postoperative complications on long-term survival and recurrence in
0
16
20
Analyses of the phase 3 CheckMate649 trial show that in patients with gastroesophageal cancer, KRAS alterations were associated with greater overall survival when treated with nivolumab plus chemotherapy vs chemotherapy alone. @yjanjigianMD @KoheiShitara
nature.com
Nature Medicine - Exploratory biomarker analyses of the phase 3 CheckMate 649 trial show that in patients with advanced gastroesophageal cancer, KRAS alterations were associated with greater...
0
6
24
CALLLING all Allied Health and Nurses interested in Upper GI diseases. We are offering 2 bursaries to support any Allied Health and Nurses attend the AANZGOSA ASM, on 17 Sept, Brisbane. Visit: https://t.co/nk28G5XdiZ Early bird: ends 14th August See you in Brisbane! @aanzgosa
0
5
5
Posted this now @biorxivpreprint ! A comprehensive effort from @mcgillu detailing progressive refinement of gastroesophageal adenocarcinoma patient-derived #organoid generation. A huge bio repository of almost 400 patient tumours! @organoidscience
https://t.co/W9M6k1D8iS
biorxiv.org
A major limitation in studying gastroesophageal adenocarcinoma (GEA) has been the lack of reliable models that represent the disease’s complexity. We present lessons learned from a comprehensive...
3
13
29
🌆 Don’t miss the #ISDE2025 Congress Dinner on Sept 19! Dine above #Brisbane at the Sky Room with iconic views, Aussie flavors, live entertainment & great company. 📍 BCEC 🕖 7–10PM 👔 Biz casual 💵 $165 USD Secure your spot now👉 https://t.co/4i9osFqjLM
#esophagus #esophageal
0
4
6
🚨 1 Week Left! Early bird registration for #ISDE2025 closes June 12! Join global experts in esophageal health Sept 18–20 in Brisbane 🇦🇺 ✅ Save up to $100 ✅ Top hotels still available ✅ Cutting-edge science & networking https://t.co/4i9osFqjLM
#ISDE #esophagus #esophageal
1
3
3
Matterhorn is out! Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | New England Journal of Medicine
nejm.org
Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig...
0
7
17
I disagree with the statement that nivo demonstrated OS survival improvement in Checkmate577, when the CI overlaps 1! I agree nivo is a clinically useful agent after CRT, especially for esoph SCC. While an ⬆️ OS is plausible, the data presented do not prove it.
0
2
3
#ASCO25 OG orals take homes: 1. CM577: adj nivo SCC only 🚫 mixed histology trials! 2. LEAP15: chemo+TKI+ICI=too much 🔎 Attention to the safety run-in 3. DG04: TDXD 1.1m PFS 3.3m OS ⬆️ 💉biopsy after 1L 4. CLD 18.2 CAR-T: 4m PFS 🔬 More work needed on tox vs efficacy
0
7
39
🚨DYNAMIC-III🚨 🔎R0 resected stage 3 colon cancer, post-op ctDNA + Randomized SoC vs intensified Systemic therapy ⛔️No improvement in RFS with intensification 🧐While ctDNA+ is prognostic, work is needed to identify how tx/selection may be altered to ⬆️outcomes #ASCO25
1
15
31
What is the optimal length of POEM for achalasia? "Standard length of peroral endoscopic myotomy (POEM) for achalasia: a systematic review and meta-analysis" https://t.co/bVxw2NsvR9
academic.oup.com
Summary. Peroral endoscopic myotomy (POEM) is an established treatment for achalasia, yet there is still a lack of technical standardization. No clear defi
0
3
6
Hot off the press! "International Society for Diseases of the Esophagus consensus on management of the failed fundoplication" #GERD #SoMe4Surgery #ISDE #EsophagealSurgery
https://t.co/koG3PXTrYa
0
11
16
Exciting to annouce, Young ISDE @ISDE_net @AfrinKamalMD @JessieAElliott has activated a database for international fellowships in esophageal diseases - for surg, gastro, scientist, allied health etc. Please enter your centre's data and spread the word.
0
5
12